

May 17, 2011
Eisai Co., Ltd.

CORRECTION TO CONSOLIDATED FINANCIAL REPORT FOR FISCAL 2010

The Consolidated Financial Report for Fiscal 2010 (fiscal year ended March 31, 2011, Japan Standard) which was released on May 13, 2011 was found to contain inaccurate information. Eisai Co., Ltd. hereby makes the following corrections.

1. Corrected Material:

Consolidated Financial Report for Fiscal 2010 (fiscal year ended March 31, 2011, Japan Standard), Section (3) Research & Development Projects, Alliances, and Other Events, Page 8, Lines 14-17.

2. Corrected Contents: *corrected part is underlined.

(Original)

○ A Phase III study of the **anticancer agent E7080** (VEGF receptor tyrosine kinase /multi-kinase inhibitor) for thyroid cancer was initiated in the U.S. In addition, a Phase III study for melanoma was initiated in Europe following commencement of the study in the U.S. A Phase II study in patients with glioma is also ongoing in the U.S.

(Corrected)

○ A Phase III study of the **anticancer agent E7080** (VEGF receptor tyrosine kinase /multi-kinase inhibitor) for thyroid cancer was initiated in the U.S. In addition, Phase II studies for endometrial cancer and melanoma were initiated in Europe following commencement of the studies in the U.S. A Phase II study in patients with glioma is also ongoing in the U.S.

Media Inquiries:

Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120